Table 3.
VACS 8 participants with OSA (n=596), by HIV infection status.
| OSA+, HIV+ (n=143) | OSA+, Uninfected (n=453) |
p-value | |
|---|---|---|---|
| DEMOGRAPHICS | |||
| Age in years, mean (SD) | 48.8 (8.9) | 50.5 (9.2) | 0.05 |
| Male gender, % | 98.6 | 93.4 | 0.02 |
| Race, % | 0.9 | ||
| Black | 57.3 | 58.9 | |
| White | 39.2 | 37.1 | |
| Other | 3.5 | 4.0 | |
| Body mass index (BMI), kg/m2,median (IQR) | 30.6 (26.0, 34.4) | 33.6 (30.0, 38.1) | <0.0001 |
| BMI <25 kg/m2, % | 14.8 | 5.6 | <0.0001 |
| BMI 25-35 kg/m2, % | 66.9 | 57.3 | |
| BMI >35 kg/m2, % | 18.3 | 37.1 | |
| CD4, median cells/ml (IQR) | 404 (257, 567) | n/a | |
| CD4 <200 cells/ml, % | 16.2 | ||
| HIV RNA, median copies/ml (IQR) | 932 (75, 20538) | n/a | |
| HIV RNA <400 copies/ml, % | 39.0 | ||
| Combination antiretroviral therapy use, % | 67.8 | n/a | |
| Smoking status, % | 0.3 | ||
| Current | 38.5 | 31.2 | |
| Former | 28.7 | 33.9 | |
| Never | 32.9 | 34.8 | |
| Hazardous alcohol use, % | 44.1 | 40.2 | 0.4 |
| COMORBIDITIES | |||
| Cardiovascular disease, % | 3.5 | 8.6 | 0.04 |
| Hypertension, % | 42.7 | 60.9 | 0.0001 |
| Diabetes, % | 43.4 | 51.7 | 0.08 |
| Chronic obstructive pulmonary disease, % | 8.4 | 9.1 | 0.8 |
| Major depression, % | 15.4 | 14.4 | 0.8 |
| Hepatitis C, % | 21.0 | 9.7 | 0.0004 |
| Hepatitis B, % | 4.2 | 1.3 | 0.03 |
|
OSA-RELATED TESTING, TREATMENT, AND
SYMPTOMS |
|||
| Polysomnogram, %* | 52.5 | 50.6 | 0.7 |
| Home sleep test, %* | 4.2 | 9.3 | 0.05 |
| CPAP CPT code, %* | 51.8 | 47.5 | 0.4 |
| Tired/fatigue, % | 67.8 | 60.0 | 0.09 |
| Concentration difficulty, % | 46.5 | 38.9 | 0.4 |
| Self-reported sleep apnea during follow-up, %** |
58.7 | 61.6 | 0.5 |
*
data include events at baseline or during follow-up
**
includes follow-up survey data from 112/143 (78%) HIV+ OSA and 332/453 (73%) uninfected OSA VACS 8 participants; p=0.2 between HIV+ OSA and uninfected OSA follow up-survey completion rate